Zosano Pharma Corporation

Add to watchlist
€0.851
Last updated:06/15/2021
0ZPN: F
Zosano Pharma Corporation

Zosano Pharma Corporation, a clinical stage biopharmaceutical company, focuses on providing therapeutics and other bioactive molecules to patients suffering from migraine using its transdermal microneedle system. Its lead product candidate is Qtrypta (M207), a proprietary formulation… Show more

P/E ratio
-
vs. 0.00x forward

Company has negative earnings per share so P/E ratio is not available.

Stock volatility (Beta)
past 12 months

Become our supporter to unlock all data!
Company results
Quarterly
Annual
Fundamentals
2017
2018
2019
2020
Net Income
Income minus expenses, depreciation, interest, taxes, and other expenses
-29.105M
-35.358M
-21.48%
-37.589M
-6.31%
-33.369M
+11.23%
Cashflow
Sum up money going in and out company
-26.839M
-29.122M
-8.51%
-34.817M
-19.56%
-31.718M
+8.90%
Total liabilities
All combined debts and obligations
10.952M
17.07M
+55.86%
28.278M
+65.66%
24.496M
-13.37%
Company profile
CEO
Mr. Steven Lo
Market capitalization
Micro (103.52M)